Shares of insulin device maker Embecta (EMBC) have fallen 55% from their 2022 spinoff. A Seeking Alpha contributor sees a turnaround driven by new products and an attractive risk/reward.
Alpha Score of 15 reflects poor overall profile with poor momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Embecta (EMBC) shares have lost more than half their value since the company was spun off from Becton Dickinson in 2022. The insulin delivery device maker now trades at about 8.5 times this year's expected earnings, a level that one Seeking Alpha contributor argues leaves room for a 40% upside to $19 a share.
The contributor, who disclosed a long position in Embecta, laid out a turnaround thesis centered on product launches and a depressed valuation. Embecta makes syringes, pen needles, and insulin pumps. It holds a roughly 70% share of the global insulin syringe market, a business that generates steady cash flow but has seen volume pressure from the rise of continuous glucose monitors and pump adoption.
The near-term catalyst, the contributor said, is a new twist pen needle that should roll out later this year. The company also has a closed-loop insulin pump in development, though that product is likely years from approval. A $100 million share buyback and insider purchases from the CEO and CFO were cited as signs of confidence.
Risks include competition from Insulet (PODD) and Tandem Diabetes Care, both of which have more advanced pump offerings. Insulet's Omnipod 5 is the market leader in tubeless pumps. The AlphaScala Alpha Score for PODD stands at 15 out of 100, classified as Weak, reflecting the competitive pressure in the insulin delivery space. Embecta's own pump, if it reaches the market, would face an uphill battle against established players.
The contributor acknowledged that Embecta's turnaround is not guaranteed. The company's core syringe business faces long-term erosion as more patients switch to pumps. But the current stock price, the contributor said, prices in a worst-case scenario. The contributor estimated Embecta can earn $1.60 in adjusted EPS for the fiscal year ending September 2025, rising to $1.00 the following year on a normalized basis. At $13.50, the stock reflects a 13.5 multiple on that normalized figure, which the contributor called cheap for a company with a dominant market share in a defensive medical niche.
Embecta reports fiscal fourth-quarter results in November. The company's next catalyst will be the rollout of the twist pen needle, which the contributor expects to be a margin driver. The insider buying and buyback authorization suggest management sees the current level as a buying opportunity, though the stock will need earnings stabilization to regain investor confidence.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.